The oncolytic peptide LTX-315 triggers necrotic cell death

Cell Cycle

Volumn 14, Issue 21, 2015, Pages 3506-3512

  Forveille, Sabrina ^a,b,c,d   Zhou, Heng ^a,b,c,d,e   Sauvat, Allan ^a,b,c,d   Bezu, Lucillia ^a,b,c,d,e   Müller, Kevin ^a,b,c,d,e   Liu, Peng ^a,b,c,d,e   Zitvogel, Laurence ^a,e,f,g   Pierron, Gérard ^a,h   Rekdal, Øystein ^i,j   Kepp, Oliver ^a,b,c,d   Kroemer, Guido ^a,b,c,d,k,l  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f INSERM   (France)

^g Center of Clinical Investigations in Biotherapies of Cancer CICBT 507   (France)

^h CNRS   (France)

ⁱ UNIVERSITY OF TROMSØ   (Norway)

^j LYTIX BIOPHARMA AS   (Norway)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Anticancer immunity; Apoptotsis; LTX 315; Necrosis

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CASPASE 3; CYCLOSPORIN A; ONCOLYTIC PEPTIDE LTX 315; POLYPEPTIDE ANTIBIOTIC AGENT; STAUROSPORINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; CYCLOSPORIN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LTX-315; NECROSTATIN-1; OLIGOPEPTIDE; PEPTIDE CHLOROMETHYL KETONE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL KILLING; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL ULTRASTRUCTURE; CELL VIABILITY; CHROMATIN; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; MORPHOLOGICAL TRAIT; MORPHOMETRICS; TRANSMISSION ELECTRON MICROSCOPY; U2OS CELL LINE; BONE NEOPLASMS; DOSE RESPONSE; METABOLISM; NECROSIS; OSTEOSARCOMA; TIME FACTOR; TUMOR CELL LINE; ULTRASTRUCTURE;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CASPASE INHIBITORS; CELL LINE, TUMOR; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; INDOLES; MICROSCOPY, ELECTRON, TRANSMISSION; NECROSIS; OLIGOPEPTIDES; OSTEOSARCOMA; TIME FACTORS;

EID: 84959454604     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1093710     Document Type: Article

References (39)

1. Javadpour MM, Juban MM, Lo WC, Bishop SM, Alberty JB, Cowell SM, Becker CL, McLaughlin ML. De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 1996; 39:3107-13; PMID:8759631; http://dx.doi.org/10.1021/jm9509410
2. Mai JC, Mi Z, Kim SH, Ng B, Robbins PD. A proapoptotic peptide for the treatment of solid tumors. Cancer Res 2001; 61:7709-12; PMID:11691780
3. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5:1032-8; PMID:10470080; http://dx.doi.org/10.1038/12469
4. Kelly KA, Jones DA. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia 2003; 5:437-44; PMID:14670181; http://dx.doi.org/10.1016/S1476-5586(03)80046-5
5. Marks AJ, Cooper MS, Anderson RJ, Orchard KH, Hale G, North JM, Ganeshaguru K, Steele AJ, Mehta AB, Lowdell MW, et al. Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. Cancer Res 2005; 65:2373-7; PMID:15781652; http://dx.doi.org/10.1158/0008-5472.CAN-04-2594
6. Mandelin J, Cardo-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, et al. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A 2015; 112:3776-81; PMID:25762070
7. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 2002; 99:1527-31; PMID:11830668; http://dx.doi.org/10.1073/pnas.241655998
8. Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med 2011; 3:108ra12; http://dx.doi.org/10.1126/scitranslmed.3002621
9. Macho A, Decaudin D, Castedo M, Hirsch T, Susin SA, Zamzami N, Kroemer G. Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis. Cytometry 1996; 25:333-40; PMID:8946140; http://dx.doi.org/10.1002/(SICI)1097-0320(19961201)25:4%3c333:: AID-CYTO4%3e3.0.CO;2-E
10. Metivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I, Kroemer G. Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett 1998; 61:157-63; PMID:9657269; http://dx.doi.org/10.1016/S0165-2478(98)00013-3
11. Penninger JM, Kroemer G. Mitochondria, AIF and caspases–rivaling for cell death execution. Nat Cell Biol 2003; 5:97-9; PMID:12563272; http://dx.doi.org/10.1038/ncb0203-97
12. Camilio KA, Berge G, Ravuri CS, Rekdal O, Sveinbjornsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother 2014; 63:601-13; PMID:24676901; http://dx.doi.org/10.1007/s00262-014-1540-0
13. Camilio KA, Rekdal O, Sveinbjornsson B. LTX-315 (Oncopore): A short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology 2014; 3:e29181; PMID:25083333; http://dx.doi.org/10.4161/onci.29181
14. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
15. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3:e955691
16. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014; 3:e28518; PMID:25071979; http://dx.doi.org/10.4161/onci.28518
17. Calvet CY, Famin D, Andre FM, Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology 2014; 3:e28131; PMID:25083316; http://dx.doi.org/10.4161/onci.28131
18. Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli E, Baracco EE, Galluzzi L, Zitvogel L, Kepp O, et al. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology 2014; 3:e28473; PMID:25050214; http://dx.doi.org/10.4161/onci.28473
19. Michaud M, Sukkurwala AQ, Di Sano F, Zitvogel L, Kepp O, Kroemer G. Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress. Oncoimmunology 2014; 3:e28276; PMID:25050202; http://dx.doi.org/10.4161/onci.28276
20. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482-91; PMID:19881547; http://dx.doi.org/10.1038/onc.2009.356
21. Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Saut_es-Fridman C, Fucikova J, Galon J, Spisek R, et al. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology 2015; 4:e1008866; PMID:26137404; http://dx.doi.org/10.1080/2162402X.2015.1008866
22. Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology 2014; 3:e954929; PMID:25941606; http://dx.doi.org/10.4161/21624011.2014.954929
23. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3:e27878; PMID:24800173; http://dx.doi.org/10.4161/onci.27878
24. Ma Y, Adjemian S, Galluzzi L, Zitvogel L, Kroemer G. Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. Oncoimmunology 2014; 3:e27663; PMID:24800170; http://dx.doi.org/10.4161/onci.27663
25. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9:353-63; PMID:19365408; http://dx.doi.org/10.1038/nri2545
26. Werthmoller N, Frey B, Wunderlich R, Fietkau R, Gaipl US. Modulation of radiochemoimmunotherapyinduced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide-and T-cell-dependent manner. Cell Death Dis 2015; 6:e1761; PMID:25973681; http://dx.doi.org/10.1038/cddis.2015.129
27. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19:107-20; PMID:21760595; http://dx.doi.org/10.1038/cdd.2011.96
28. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015; 22:58-73; PMID:25236395; http://dx.doi.org/10.1038/cdd.2014.137
29. Tailler M, Senovilla L, Lainey E, Thepot S, Metivier D, Sebert M, Baud V, Billot K, Fenaux P, Galluzzi L, et al. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene 2012; 31:3536-46; PMID:22105358; http://dx.doi.org/10.1038/onc.2011.521
30. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10:221-37; PMID:21358741; http://dx.doi.org/10.1038/nrd3373
31. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1:112-9; PMID:16408008; http://dx.doi.org/10.1038/nchembio711
32. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014; 370:455-65; PMID:24476434; http://dx.doi.org/10.1056/NEJMra1310050
33. Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell death. Science 2014; 345:1250256; PMID:25237106; http://dx.doi.org/10.1126/science.1250256
34. Zhou H, Forveille S, Sica V, Izzo V, Durand S, Müller K, Liu P, Zitvogel L, Rekdal Ø, Kepp O, et al. The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget 2015; 6 (29):26599-614
35. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780-8; PMID:23175281; http://dx.doi.org/10.1038/nrm3479
36. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013; 12:829-46; PMID:24113830; http://dx.doi.org/10.1038/nrd4145
37. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupé P, Robert T, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70:1793-803; PMID:20145152; http://dx.doi.org/10.1158/0008-5472.CAN-09-3112
38. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; 73:2271-80; PMID:23554447; http://dx.doi.org/10.1158/0008-5472.CAN-12-3000
39. Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 2014; 74:436-45; PMID:24302580; http://dx.doi.org/10.1158/0008-5472.CAN-13-1265